PATRICIA SOBLECHERO MARTÍN-rekin lankidetzan egindako argitalpenak (6)

2022

  1. Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy

    Methods in Molecular Biology (Humana Press Inc.), pp. 217-233

  2. Lessons learned from developing an oligonucleotide drug for a rare disease

    RNA Therapeutics: The Evolving Landscape of RNA Therapeutics (Elsevier), pp. 121-137

  3. miR-106b is a novel target to promote muscle regeneration and restore satellite stem cell function in injured Duchenne dystrophic muscle

    Molecular Therapy - Nucleic Acids, Vol. 29, pp. 769-786

2021

  1. Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening

    Scientific Reports, Vol. 11, Núm. 1

  2. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies

    Neuropathology and Applied Neurobiology, Vol. 47, Núm. 6, pp. 711-723

2020

  1. An overview of alternative splicing defects implicated in myotonic dystrophy type i

    Genes, Vol. 11, Núm. 9, pp. 1-27